BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12921476)

  • 1. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.
    McGough JJ; Biederman J; Greenhill LL; McCracken JT; Spencer TJ; Posner K; Wigal S; Gornbein J; Tulloch S; Swanson JM
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):684-91. PubMed ID: 12921476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.
    McCracken JT; Biederman J; Greenhill LL; Swanson JM; McGough JJ; Spencer TJ; Posner K; Wigal S; Pataki C; Zhang Y; Tulloch S
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):673-83. PubMed ID: 12921475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.
    Biederman J; Lopez FA; Boellner SW; Chandler MC
    Pediatrics; 2002 Aug; 110(2 Pt 1):258-66. PubMed ID: 12165576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
    Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
    J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adderall XR: long acting stimulant for single daily dosing.
    Sallee FR; Smirnoff AV
    Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD.
    Greenhill LL; Swanson JM; Steinhoff K; Fried J; Posner K; Lerner M; Wigal S; Clausen SB; Zhang Y; Tulloch S
    J Am Acad Child Adolesc Psychiatry; 2003 Oct; 42(10):1234-41. PubMed ID: 14560174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
    Clausen SB; Read SC; Tulloch SJ
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):6-15. PubMed ID: 16344836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
    McGough JJ; Biederman J; Wigal SB; Lopez FA; McCracken JT; Spencer T; Zhang Y; Tulloch SJ
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder.
    Grcevich S
    Expert Opin Investig Drugs; 2001 Nov; 10(11):2003-11. PubMed ID: 11772303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.
    James RS; Sharp WS; Bastain TM; Lee PP; Walter JM; Czarnolewski M; Castellanos FX
    J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1268-76. PubMed ID: 11699800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration.
    Tulloch SJ; Zhang Y; McLean A; Wolf KN
    Pharmacotherapy; 2002 Nov; 22(11):1405-15. PubMed ID: 12432966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR; Browne RG; Olvera RL; Wynne SK
    J Am Acad Child Adolesc Psychiatry; 2000 May; 39(5):619-26. PubMed ID: 10802980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.
    Findling RL; Biederman J; Wilens TE; Spencer TJ; McGough JJ; Lopez FA; Tulloch SJ;
    J Pediatr; 2005 Sep; 147(3):348-54. PubMed ID: 16182674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.